NO933960D0 - INTERLEUKIN RECEPTOR-TARGETING MOLECULES FOR TREATMENT OF INFLAMMATORY ARTHRITIS - Google Patents
INTERLEUKIN RECEPTOR-TARGETING MOLECULES FOR TREATMENT OF INFLAMMATORY ARTHRITISInfo
- Publication number
- NO933960D0 NO933960D0 NO1993933960A NO933960A NO933960D0 NO 933960 D0 NO933960 D0 NO 933960D0 NO 1993933960 A NO1993933960 A NO 1993933960A NO 933960 A NO933960 A NO 933960A NO 933960 D0 NO933960 D0 NO 933960D0
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- targeting molecules
- inflammatory arthritis
- interleukin receptor
- interleukin
- Prior art date
Links
- 102000015696 Interleukins Human genes 0.000 title 1
- 108010063738 Interleukins Proteins 0.000 title 1
- 206010003246 arthritis Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69548091A | 1991-05-03 | 1991-05-03 | |
| US87652192A | 1992-04-30 | 1992-04-30 | |
| PCT/US1992/003714 WO1992019259A1 (en) | 1991-05-03 | 1992-05-04 | Interleukin receptor targeted molecules for treatment of inflammatory arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO933960D0 true NO933960D0 (en) | 1993-11-02 |
| NO933960L NO933960L (en) | 1993-12-28 |
Family
ID=27105578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO933960A NO933960L (en) | 1991-05-03 | 1993-11-02 | Interleukin receptor targeting molecules for the treatment of inflammatory arthritis |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0668774A1 (en) |
| JP (1) | JPH06510750A (en) |
| AU (1) | AU665763B2 (en) |
| BR (1) | BR9205967A (en) |
| CA (1) | CA2108886A1 (en) |
| NO (1) | NO933960L (en) |
| WO (1) | WO1992019259A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| HUE064945T2 (en) | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| TWI633891B (en) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
| TWI682781B (en) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
| RU2704999C2 (en) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Method of treating skin infection by administering antagonist il-4r |
| EP3218412A1 (en) | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| EP4442323A3 (en) | 2016-09-01 | 2025-01-01 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| TWI857389B (en) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | Methods of treating inflammatory conditions |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| MA46269B1 (en) | 2017-08-18 | 2024-05-31 | Regeneron Pharma | METHODS OF TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTRATION OF AN IL-4R INHIBITOR |
| HUE064655T2 (en) | 2017-10-30 | 2024-04-28 | Sanofi Biotechnology | IL-4R antagonist in a method for treating or preventing asthma |
| CN112153982A (en) | 2018-05-13 | 2020-12-29 | 瑞泽恩制药公司 | Methods for treating atopic dermatitis by administering IL-4R inhibitors |
| MX2021011141A (en) | 2019-03-21 | 2022-01-19 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy. |
| MX2022000649A (en) | 2019-07-16 | 2022-06-08 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist. |
| AU2020326713A1 (en) | 2019-08-05 | 2022-02-17 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| EP4010001A1 (en) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE448386B (en) * | 1978-10-18 | 1987-02-16 | Sandoz Ag | NEW CYCLOSPORIN DERIVATIVES, PROCEDURE FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
| DE3369466D1 (en) * | 1982-05-12 | 1987-03-05 | Harvard College | Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof |
| US5080898A (en) * | 1982-05-12 | 1992-01-14 | The University Hospital | Enzymatically active toxin coupled to a cell-specific ligand |
| IL89504A0 (en) * | 1988-03-08 | 1989-09-10 | Univ Wyoming | Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same |
| WO1992006117A1 (en) * | 1990-09-28 | 1992-04-16 | Seragen, Inc. | Inhibiting unwanted immune responses |
-
1992
- 1992-05-04 BR BR9205967A patent/BR9205967A/en not_active Application Discontinuation
- 1992-05-04 AU AU19927/92A patent/AU665763B2/en not_active Ceased
- 1992-05-04 WO PCT/US1992/003714 patent/WO1992019259A1/en not_active Ceased
- 1992-05-04 CA CA002108886A patent/CA2108886A1/en not_active Abandoned
- 1992-05-04 EP EP92912075A patent/EP0668774A1/en not_active Withdrawn
- 1992-05-04 JP JP4511998A patent/JPH06510750A/en active Pending
-
1993
- 1993-11-02 NO NO933960A patent/NO933960L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9205967A (en) | 1994-07-26 |
| AU665763B2 (en) | 1996-01-18 |
| NO933960L (en) | 1993-12-28 |
| JPH06510750A (en) | 1994-12-01 |
| EP0668774A1 (en) | 1995-08-30 |
| EP0668774A4 (en) | 1995-04-25 |
| CA2108886A1 (en) | 1992-11-04 |
| AU1992792A (en) | 1992-12-21 |
| WO1992019259A1 (en) | 1992-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO933960D0 (en) | INTERLEUKIN RECEPTOR-TARGETING MOLECULES FOR TREATMENT OF INFLAMMATORY ARTHRITIS | |
| NO934304D0 (en) | Process for the treatment of fluoroalumosilicate glass | |
| NO305288B1 (en) | Process for the production of hydrocarbon fuels | |
| FI103570B1 (en) | Process for the purification of carboxylic acids and / or anhydrides thereof | |
| DK0551476T4 (en) | Apparatus for the production of mineral wool | |
| FI945549A7 (en) | Purified forms of deoxyribonuclease | |
| FI962429A0 (en) | Probiot for control of salmonella | |
| BE881963A (en) | WASTEWATER TREATMENT PLANT | |
| NO930347D0 (en) | PROCESS FOR GASPHASE POLYMERIZATION OF ALFA OLEFINES | |
| MX9200148A (en) | MANUFACTURE OF BODIES OF CORDIERITA | |
| MX9200152A (en) | MANUFACTURE OF BODIES OF CORDIERITA | |
| EP0468181A3 (en) | Process for the purification of factor viii and factor viii obtained by said process | |
| TW222638B (en) | ||
| FI960400A0 (en) | Process for crystallization of iopamidol | |
| DE69312205D1 (en) | Purification method of raw product | |
| NO996324D0 (en) | Process for the preparation of intermediates in the synthesis of benzopyran compounds | |
| IT1158044B (en) | PURIFICATION OF CARBONILATION PRODUCTS | |
| KR930702469A (en) | Improved recycling method of linear paraffin purification method | |
| FI962097A0 (en) | Process for making hard elements of wood | |
| FI934797L (en) | PRODUCTION OF CABLES | |
| NO961747D0 (en) | Treatment of rheumatoid arthritis | |
| DE69417915D1 (en) | PURIFICATION OF URANHEXAFLUORID | |
| KR950701894A (en) | PRODUCTION OF HYDROFLUOROALKANES | |
| NO940190L (en) | Use of alpha-ketoglutarate | |
| FI940265L (en) | Continuous process for the industrial production of dimethoxyethanal |